42 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
. In particular, global economic markets have seen extensive volatility over the past few years owing to the outbreak of the COVID-19 pandemic, the war … manner, including as a result of circumstances relating to the COVID-19 pandemic, our clinical trials may be delayed and our business may be adversely
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
. In particular, global economic markets have seen extensive volatility over the past few years owing to the outbreak of the COVID-19 pandemic, the war … manner, including as a result of circumstances relating to the COVID-19 pandemic, our clinical trials may be delayed and our business may
424B5
XRTX
XORTX Therapeutics Inc
29 Nov 23
Prospectus supplement for primary offering
9:57pm
and anticipated cash needs;
the impact of the COVID-19 pandemic on the business and operations of the Company; and
general market conditions … and macroeconomic trends driven by the COVID-19 pandemic and/or geopolitical conflicts, including supply chain disruptions, market volatility, inflation, and labor
6-K
EX-99.1
XRTX
XORTX Therapeutics Inc
16 May 23
Condensed Interim Consolidated Financial Statements
9:32am
coronavirus COVID-19 a global pandemic. In May 2023, the International Health Regulations (IHR) Emergency Committee of the WHO downgraded the COVID-19 … pandemic as it is now and established and ongoing health issue which no longer constitutes a public health emergency of international concern
6-K
EX-99.2
hawlk03m1xk0450r
16 May 23
Condensed Interim Consolidated Financial Statements
9:32am
6-K
EX-99.3
4gm97x
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.2
auqp9aepanpqom
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.1
4g9j88
3 Apr 23
Consolidated Financial Statements
6:05am
424B3
yjkaz 0az8w
14 Nov 22
Prospectus supplement
1:51pm
6-K
EX-99.2
ubqqzp
14 Nov 22
Condensed Interim Consolidated Financial Statements
1:04pm
6-K
EX-99.1
uqp me57ozhengmb
14 Nov 22
Condensed Interim Consolidated Financial Statements
1:04pm
424B4
68qotu0 02s
5 Oct 22
Prospectus supplement with pricing info
5:24pm
POS AM
mp4o78obi9kcdf
29 Sep 22
Prospectus update (post-effective amendment)
9:49pm
F-1/A
vq30npmzlai58 sgtt
21 Sep 22
Registration statement (foreign) (amended)
4:20pm
F-1
o6q4wtnv11b37aut
8 Sep 22
Registration statement (foreign)
1:02pm
DRS
ekqqqvzwvtng
15 Aug 22
Draft registration statement
12:00am
6-K
EX-99.2
txt yasntqnd
11 Aug 22
Condensed Interim Consolidated Financial Statements
7:00am